253 related articles for article (PubMed ID: 29353083)
41. Inhalable functional mixed-polymer microspheres to enhance doxorubicin release behavior for lung cancer treatment.
Li W; Chen S; Zhang L; Zhang Y; Yang X; Xie B; Guo J; He Y; Wang C
Colloids Surf B Biointerfaces; 2020 Dec; 196():111350. PubMed ID: 32911292
[TBL] [Abstract][Full Text] [Related]
42. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic efficacy of DNA-loaded PLGA microspheres in tumor-bearing mice.
Son HJ; Kim JS
Arch Pharm Res; 2007 Aug; 30(8):1047-50. PubMed ID: 17879760
[TBL] [Abstract][Full Text] [Related]
44. Local penetration of doxorubicin via intrahepatic implantation of PLGA based doxorubicin-loaded implants.
Gao L; Li Q; Zhang J; Huang Y; Deng L; Li C; Tai G; Ruan B
Drug Deliv; 2019 Dec; 26(1):1049-1057. PubMed ID: 31691602
[TBL] [Abstract][Full Text] [Related]
45. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
[TBL] [Abstract][Full Text] [Related]
46. Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment.
Rong ZJ; Yang LJ; Cai BT; Zhu LX; Cao YL; Wu GF; Zhang ZJ
J Mater Sci Mater Med; 2016 May; 27(5):89. PubMed ID: 26975746
[TBL] [Abstract][Full Text] [Related]
47. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment.
Ma H; He C; Cheng Y; Li D; Gong Y; Liu J; Tian H; Chen X
Biomaterials; 2014 Oct; 35(30):8723-34. PubMed ID: 25017095
[TBL] [Abstract][Full Text] [Related]
48. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
49. Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model.
Ozeki T; Kaneko D; Hashizawa K; Imai Y; Tagami T; Okada H
Biol Pharm Bull; 2012; 35(4):545-50. PubMed ID: 22466559
[TBL] [Abstract][Full Text] [Related]
50. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments.
Park H; Yang J; Lee J; Haam S; Choi IH; Yoo KH
ACS Nano; 2009 Oct; 3(10):2919-26. PubMed ID: 19772302
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy.
He P; Xu S; Guo Z; Yuan P; Liu Y; Chen Y; Zhang T; Que Y; Hu Y
Drug Deliv; 2022 Dec; 29(1):478-488. PubMed ID: 35147071
[TBL] [Abstract][Full Text] [Related]
52. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
Park J; Fong PM; Lu J; Russell KS; Booth CJ; Saltzman WM; Fahmy TM
Nanomedicine; 2009 Dec; 5(4):410-8. PubMed ID: 19341815
[TBL] [Abstract][Full Text] [Related]
53. [Formulation and process optimization of doxorubicin-loaded PLGA nanoparticles and its in vitro release].
Li JL; Zheng CL; Liu JP; Zhu JB
Yao Xue Xue Bao; 2013 May; 48(5):759-66. PubMed ID: 23888702
[TBL] [Abstract][Full Text] [Related]
54. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles.
Lin R; Shi Ng L; Wang CH
Biomaterials; 2005 Jul; 26(21):4476-85. PubMed ID: 15701377
[TBL] [Abstract][Full Text] [Related]
55. Application of Doxorubicin-loaded PLGA nanoparticles targeting both tumor cells and cancer-associated fibroblasts on 3D human skin equivalents mimicking melanoma and cutaneous squamous cell carcinoma.
He Y; Wu S; Rietveld M; Vermeer M; Cruz LJ; Eich C; El Ghalbzouri A
Biomater Adv; 2024 Jun; 160():213831. PubMed ID: 38552501
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of 3-D tumor spheroids by timed-released hydrophilic and hydrophobic drugs from multilayered polymeric microparticles.
Lee WL; Guo WM; Ho VH; Saha A; Chong HC; Tan NS; Widjaja E; Tan EY; Loo SC
Small; 2014 Oct; 10(19):3986-96. PubMed ID: 24947558
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the effects of ultrasound in a repetitive mode and acoustically active lipospheres in the presence of doxorubicin on breast adenocarcinoma.
Soleimani H; Abdolmaleki P; Mokhtari-Dizaji M; Toliat T; Tavasoly A
J Cancer Res Ther; 2020; 16(6):1250-1257. PubMed ID: 33342780
[TBL] [Abstract][Full Text] [Related]
58. Specific targeting of A54 homing peptide-functionalized dextran-g-poly(lactic-co-glycolic acid) micelles to tumor cells.
Situ JQ; Ye YQ; Zhu XL; Yu RS; You J; Yuan H; Hu FQ; Du YZ
Int J Nanomedicine; 2015; 10():665-75. PubMed ID: 25653517
[TBL] [Abstract][Full Text] [Related]
59. Using acoustic cavitation to enhance chemotherapy of DOX liposomes: experiment in vitro and in vivo.
Zhao YZ; Dai DD; Lu CT; Lv HF; Zhang Y; Li X; Li WF; Wu Y; Jiang L; Li XK; Huang PT; Chen LJ; Lin M
Drug Dev Ind Pharm; 2012 Sep; 38(9):1090-8. PubMed ID: 22188116
[TBL] [Abstract][Full Text] [Related]
60. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation.
Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM
Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
